Disruption of the p53 pathway in HCC can either occur by mutations of p53 itself, by alterations in pathways that regulate protein stability such as interaction with its specific inhibitor MDM2 [44], and post-translational modifications such as protein acetylation which lead to enhanced activity. This evidence concerns the gene MDM2 and hepatocellular carcinoma.